Ceftazidime/Avibactam and Other Commonly Used Antibiotics Activity Against Enterobacterales and Pseudomonas aeruginosa Isolated in Poland in 2015–2019

References

• Sader H, Castanheira M, Shortridge D, Mendes R, Flamm R. Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. Medical Centers, 2013 to 2016. Antimicrob Agents Chemother. 2017;61(11). doi:10.1128/aac.01045-17
   Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17(12):1798–1803. doi:10.1111/j.1469-0691.2011.03514.x
   PubMed Web of Science ®Google Scholar
• Jean S, Gould I, Lee W, Hsueh P. New drugs for multidrug-resistant gram-negative organisms: time for stewardship. Drugs. 2019;79(7):705–714. doi:10.1007/s40265-019-01112-1
   PubMed Web of Science ®Google Scholar
• Kowalska-Krochmal B, Woroń J, Serednicki WT, et al. Ceftazidime with avibactam - the microbiological, pharmacological and clinical aspect of drug use in clinical practice. Forum Zakazen. 2019;10(6). doi:10.15374/FZ2019056
   Google Scholar
• Wolska K, Kot B, Piechota M, Frankowska A. Resistance of Pseudomonas aeruginosa to antibiotics. Postepy Higieny i Medycyny Doswiadczalnej. 2013;67:1300–1311. doi:10.5604/17322693.1080803
   Web of Science ®Google Scholar
• Zalas-Więcek P, Gospodarek-Komkowska E. Antimicrobial susceptibility of multi-drug and extensively-drug-resistant Escherichia coli to ceftolozane-tazobactam and ceftazidime-avibactam: an in vitro study*. Postepy Higieny i Medycyny Doswiadczalnej. 2020;74:77–83. doi:10.5604/01.3001.0014.0859
   Web of Science ®Google Scholar
• Deptuła A, Trejnowska E, Ozorowski T, Pawlik K, Hryniewicz W. Spot study of healthcare associated infections and antibiotic use in acute care hospitals (PPS HAI & AU) in Poland. Report from a study conducted in 2014-2015. National Antibiotic Protection Program (online); 2016. Available from: http://antybiotyki.edu.pl/wp-content/uploads/dokumenty/raport_PPS_20160110.pdf. Accessed February 22, 2022.
   Google Scholar
• Jean S, Lee W, Lam C, Hsu C, Chen R, Hsueh P. Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options. Future Microbiol. 2015;10(3):407–425. doi:10.2217/fmb.14.135
   PubMed Web of Science ®Google Scholar
• Falcone M, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016;71(10):2713–2722. doi:10.1093/jac/dkw239
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Zavicefta: summary of product characteristics; 2018. Available from: http://www.ema.europa.eu. Accessed September 27 2021.
   Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard—Eleventh Edition. CLSI document M07-A10. Wayne, Pennsylvania; USA: Clinical and Laboratory Standards InstituteCLSI; 2018.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:1469–1691.
   Web of Science ®Google Scholar
• Lob S, Kazmierczak K, Badal R, et al. Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013. Antimicrob Agents Chemother. 2015;59(6):3606–3610. doi:10.1128/aac.05186-14
   PubMed Web of Science ®Google Scholar
• Nichols W, de Jonge B, Kazmierczak K, Karlowsky J, Sahm D. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother. 2016;60(8):4743–4749. doi:10.1128/aac.00220-16
   Web of Science ®Google Scholar
• Antimicrobial resistance in the EU/EEA (EARS-Net) Annual Epidemiological Report for 2019. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/surveillance-antimicrobial-resistance-Europe-2019.pdf. Accessed February 22, 2022.
   Google Scholar
• Kaye K, Pogue J. Infections caused by resistant Gram-negative bacteria: epidemiology and management. Pharmacotherapy. 2015;35(10):949–962. doi:10.1002/phar.1636
   PubMed Web of Science ®Google Scholar
• Ramalheira E, Stone G. Longitudinal analysis of the in vitro activity of ceftazidime/avibactam versus Enterobacteriaceae, 2012–2016. J Glob Antimicrob Resist. 2019;19:106–115. doi:10.1016/j.jgar.2019.07.003
   Web of Science ®Google Scholar
• Kristóf K, Adámková V, Adler A, et al. In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014–2017 and 2018. Diagn Microbiol Infect Dis. 2021;101(1):115420. doi:10.1016/j.diagmicrobio.2021.115420
   Web of Science ®Google Scholar
• Hirsch E, Brigman H, Zucchi P, et al. Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres. J Glob Antimicrob Resist. 2020;22:689–694. doi:10.1016/j.jgar.2020.04.017
   PubMed Web of Science ®Google Scholar
• Spiliopoulou I, Kazmierczak K, Stone G. In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015–17). J Antimicrob Chemother. 2019;75(2):384–391. doi:10.1093/jac/dkz456
   Web of Science ®Google Scholar
• Martis N, Leroy S, Blanc V. Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections. J Infect. 2014;69(1):1–12. doi:10.1016/j.jinf.2014.03.001
   PubMed Web of Science ®Google Scholar
• Tamma P, Aitken S, Bonomo R, Mathers A, van Duin D, Clancy C. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2020;72(7):e169–e183. doi:10.1093/cid/ciaa1478
   Web of Science ®Google Scholar
• Stone G, Smayevsky J, Kazmierczak K. Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012–2016. Diagn Microbiol Infect Dis. 2020;96(1):114835. doi:10.1016/j.diagmicrobio.2019.05.007
   Web of Science ®Google Scholar
• Sader H, Huband M, Duncan L, Flamm R. Ceftazidime–avibactam antimicrobial activity and spectrum when tested against Gram-negative organisms from pediatric patients. Pediatr Infect Dis J. 2018;37(6):549–554. doi:10.1097/inf.0000000000001859
   Web of Science ®Google Scholar
• Gill C, Aktaþ E, Alfouzan W, et al. The ERACE-PA Global Surveillance Program: ceftolozane/tazobactam and ceftazidime/avibactam in vitro activity against a global collection of carbapenem-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2021;40(12):2533–2541. doi:10.1007/s10096-021-04308-0
   PubMed Web of Science ®Google Scholar